Replies to post #33976 on Revive Therapeutics Ltd (RVVTF)

[Ecomike]

1) The largest group, over 500 people, at double the dose of the first 210, data set is not even unmasked yet.

2) The latest science, shows that all, and I mean all autoimmune diseases are tied to micro-blood-clots. Including the RA Bucillamine has used for 32 years safely for. And we know from a Bucci study that it dissolves micro blood clots as a side effect of its original primary intended use, regenerating Glutathione.

https://www.news-medical.net/news/20221018/New-research-finds-microclotting-and-inflammatory-molecule-abnormalities-in-long-COVID.aspx

Something that there was no proof of until a few months ago. I shared the study data research paper here already. 99.5% of the medical docs do not read recent studies, and most have no clue how to read them anyway.
MF needs to gather the data on it and the Bucillamine papers on what it does for blood clots, and add that the FDA updates... and to what he shows new PP investors!!! And he may need to hire a pro team like Bixt did in recent weeks to package it all to sell / close the funding deal. Here is the paper I am talking about: Massive, super impressive 47 page packet hot off the press for a firm that has not even started the phase III trial for Covid19.
They could be next Moderna? But their product will not solve long haul micro blood clot autoimmune long haul covid caused by micro-clots. It only eliminates the virus.

https://www.nasdaq.com/press-release/bioxytran-inc.-announces-the-reinitiation-of-coverage-of-its-stock-by-avise-analytics

https://cdn.discordapp.com/attachments/993933888520998937/1044741830446698586/735616179-1669115349-ReinitiationCoverageonBioxytranBIXT.pdf

$RVVTF needs to get those kind of pros to package a new updated Investors and retail package update of the entire story as it is now.

3) Then add this: https://www.cnbc.com/2022/11/30/why-long-covid-could-be-the-next-public-health-disaster.html

4) Folks need to get it through their heads that the FDA could have just said no, to the end point change request, but instead said lets discuss it!!! Before the last 500+ data set for 2X dosed people is opened. (2x higher dose than the first 210)

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

https://www.yahoo.com/now/revive-therapeutics-announces-fda-recommendation-142000793.html

Funding Biotechs was easy and money was cheap 1-2 years ago.

All Biotechs are and have been selling off, for most of this year, not just $RVVTF because of the FED jacking up interest rates. Which sucks for the new drug firms... This is not just an RVVTF share price issue.

Time to up our game plan people...

This Bucillamine drug could end up being used world wide for all auto-immune diseases based on the above new data... And it has a 32 year safe use history.